Guihua Wang Qin Chai Yajie Xiao Wenying Peng Miao Teng Jingyi Wang Hanqing Lin Xiaofan Su Lin Wu
10.3389/fimmu.2020.607416
Front Immunol
2021 Jan 28;11:607416.
cd8(+) tumor-infiltrating lymphocytes pd-l1 expression chemo-immunotherapy large cell lung carcinoma predictive biomarker tumor mutational burden
CC BY
https://pubmed.ncbi.nlm.nih.gov/33584678/
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use B7-H1 Antigen / antagonists & inhibitors CD8-Positive T-Lymphocytes / drug effects Carcinoma, Large Cell / drug therapy Immune Checkpoint Inhibitors / therapeutic use Lung Neoplasms / drug therapy Lymphocytes, Tumor-Infiltrating / drug effects
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use B7-H1 Antigen / antagonists & inhibitors CD8-Positive T-Lymphocytes / drug effects Carcinoma, Large Cell / drug therapy Immune Checkpoint Inhibitors / therapeutic use Lung Neoplasms / drug therapy Lymphocytes, Tumor-Infiltrating / drug effects Case Reports Research Support, Non-U.S. Gov't Adult B7-H1 Antigen / metabolism CD8-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / metabolism Carcinoma, Large Cell / immunology Carcinoma, Large Cell / metabolism Carcinoma, Large Cell / pathology Cisplatin / therapeutic use Humans Lung Neoplasms / immunology Lung Neoplasms / metabolism Lung Neoplasms / pathology Lymphocytes, Tumor-Infiltrating / immunology Lymphocytes, Tumor-Infiltrating / metabolism Male Paclitaxel / therapeutic use Remission Induction Treatment Outcome Tumor Microenvironment Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors pembrolizumab Paclitaxel Cisplatin
PMC7876253
33584678
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers
2021